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Highlights 
 Four novel mutations of the VCP gene  that manifest as classic VCP disease 
 Families with VCP disease expand phenotype to include Parkinson’s disease 
 Early recognition can prevent complications such as fractures from Paget disease 
 
Abstract (200 words) 
Over fifty missense mutations in the gene coding for valosin-containing protein (VCP) 
are associated with a unique autosomal dominant adult onset progressive disease 
associated with combinations of proximo-distal inclusion body myopathy (IBM), Paget’s 
disease of bone (PDB), frontotemporal dementia (FTD), and amyotrophic lateral 
sclerosis (ALS). We report the clinical, histological, and molecular findings in four new 
patients/families carrying novel VCP mutations: c.474 G>A (p.M158I); c.478 G>C 
(p.A160P); c.383G>C (p.G128A); and c.382G>T (p.G128C). Clinical features included 
myopathy, PDB, ALS and Parkinson’s disease though frontotemporal dementia was not 
an associated feature in these families. One of the patients was noted to have severe 
manifestations of PDB and was suspected of having neoplasia. There was wide inter 
and intra-familial variation making genotype-phenotype correlations difficult between the 
novel mutations and frequency or age of onset of IBM, PDB, FTD, ALS and Parkinson’s 
disease. Increasing awareness of the full spectrum of clinical presentations will improve 
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diagnosis of VCP-related diseases and thus proactively manage or prevent associated 




Inclusion body myopathy associated with Paget’s disease of bone and frontotemporal 
dementia (IBMPFD) or multisystem proteinopathy is an adult-onset progressive, 
autosomal dominant inherited, ultimately lethal disease caused by heterozygous 
missense mutations in valosin-containing protein (VCP) [1, 2]. The disease involves 
degeneration of three main organ systems: muscle, bone, and brain. As awareness 
increases, we are realizing that VCP disease is not as rare as previously considered.  
 
1.1. Pathology of IBMPFD 
Inclusion body myopathy is characterized by progressive weakness and atrophy of 
skeletal muscles of pelvic and shoulder girdle muscles [3, 4], though distal myopathy 
has been reported [5]. Characteristic histological findings include cytoplasmic rimmed 
vacuoles containing some of the proteins that aggregate in the brains of patients with 
neurodegenerative diseases: tau, amyloid, and TDP-43 (TAR DNA binding protein 43) 
[6]. Ultimately, patients die from respiratory failure, cardiomyopathy and cardiac failure 
[2, 7].  
 
VCP disease has also been associated with a spectrum of other diseases including 
amyotrophic lateral sclerosis (ALS) [8], hereditary spastic paraplegia [9], Charcot-Marie-
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Tooth Type 2 disease [10]. Other common disorders that have a clinical overlap with 
VCP disease include facioscapulohumeral muscular dystrophy (FSHD), Limb-girdle 
muscular dystrophy (LGMD), scapuloperoneal muscular dystrophy (SPMD), sporadic 
inclusion body myositis (sIBM), myofibrillar myopathies, and distal 
myopathy/oculopharyngeal muscular dystrophy [4]. 
 
Paget’s disease of bone (PDB) is a unique skeletal disease caused by an imbalance 
between overactive osteoclast and osteoblast function. The result is a gain in bone 
mass, but the new bone is disorganized, weak, and prone to fractures. Typical 
radiological findings of PDB include coarse trabeculation, cortical thickening and spotty 
sclerosis. Clinical features include bone pain, bone enlargement, fractures, hearing loss 
due to defective bone remodeling in the middle and inner ear, and arthritis. Rare 
complications include kidney stones, osteosarcoma and high-output heart failure due to 
the formation of arteriovenous shunts in bone [11]. 
 
Frontotemporal dementia (FTD) is typically diagnosed in people 45-64 years old [12], 
however in VCP disease it can be associated with an earlier age of onset. Degeneration 
and atrophy of the frontal and temporal lobes of the brain results in changes in 
personality and progressive loss of language. Brain histology in patients with IBMPFD 
affected by FTD is characterized by gliosis, spongiosis, and neuronal intranuclear 
inclusions [13]. TDP-43 aggregates are commonly associated with VCP-associated FTD 
as well as in amyotrophic lateral sclerosis (ALS) [6, 14, 15]. TDP-43 is a DNA/RNA-
binding protein involved in various cellular processes including RNA transcription and 
splicing [16-18]. We have previously shown that the presence of one or two APOE4 
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alleles is associated with an increased risk of developing FTD in patients with VCP 
mutations [19]. 
 
1.2. Mutations of VCP 
VCP has four domains: an N-terminal ubiquitin binding domain, two ATPase domains 
(D1 and D2), and a C-terminal region [20]. Valosin is a 25 amino acid peptide named 
after its N-terminal valine and C-terminal tyrosine, and was originally isolated from 
porcine gut [21]. That peptide sequence is present in valosin-containing protein, which 
is a highly abundant ATPase found in all cells where it interacts with various adaptor 
proteins to carry out many essential cellular processes. Among them are endoplasmic 
reticulum-associated degradation [22] and formation [23], transcription factor processing 
[24], nuclear envelope reconstruction [25], membrane fusion [26], post mitotic golgi 
reassembly [27], spindle disassembly [28], and cell cycle control [29]. Several of these 
activities are associated with the ubiquitin-proteasome system in which VCP helps 
deliver ubiquitylated substrates to the 26S proteasome for degradation [30]. VCP’s role 
in protein degradation and autophagy is implicated in the pathogenesis of IBMPFD, and 
may account for the protein aggregations/cytoplasmic inclusions observed in muscle, 
bone, and neuronal tissue [1, 30]. Currently, over 50 mutations have been identified in 
VCP disease (Figure 7A) [31-36]. Since our previously report of phenotype-genotype 
correlations [2], several other reports have expanded the phenotypic spectrum 
associated with VCP mutations to include Charcot-Marie-Tooth type 2 disease (CMT2) 
[10, 37], Parkinson’s disease [17], and anal incontinence [38]. In this report, we describe 
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the clinical features in four patients/families with multisystem proteinopathy associated 
with novel VCP gene mutations. 
 
2. Case Report 
Informed consent was obtained for this study as approved by University of California, 
Irvine Institutional Review Board. Medical records of individuals were reviewed for 
medical complications, progress of disease, and studies of lab values, radiology, 
electromyograms, nerve conduction studies, and muscle biopsies.  Clinical features of 
individuals from the unrelated families are summarized in Table 1. 
 
2.1. Family 1 (c.474 G>A VCP; p.M158I) 
The proband (IV:1) (Figure 1A) is a 44 year old male who initially developed progressive 
fatigue, low back pain, and bilateral hip pain in his late 20's to early 30's. He sought 
medical care at age 39 years when he was unable to walk more than a few minutes 
without resting. He was evaluated and tested for facioscapulohumeral muscular 
dystrophy (FSHD) however molecular testing for a deletion on chromosome 4q35 was 
negative. At age 42 years he started using a walker, and two years later started using a 
power chair. Co-morbidities included hypertension, type 2 diabetes mellitus, obstructive 
sleep apnea, and urinary and fecal incontinence. On physical exam, upper extremity 
strength testing revealed asymmetric periscapular weakness worse on the right, and 
Medical Research Council (MRC) scale 4/5 of the external rotator, biceps and triceps 
bilaterally, with normal grip strength. Lower extremity strength testing revealed ability to 
toe walk but not heel walk, bilateral dorsiflexor weakness right 4/5 and MRC 4+/5 in hip 
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and knee flexion and extension. Physical exam also revealed mild sensory loss over 
distribution of the left lateral femoral cutanous nerve and absent to reduced deep 
tendon reflexes in the different muscle groups. He was able to repeat and name objects 
and follow complex commands without difficulty, had memory intact for recent and 
remote events, and had fluent speech. His frontal behavioral inventory (FBI) was not 
suggestive of FTD. Electromyogram testing of the left dorsal interossei, extensor carpi 
radialis, bicep, tibialis anterior, vastus medialis, and rectus femoris, showed short 
duration, low amplitude motor unit potentials with an early recruitment pattern in 
selected muscles, electrophysiologic evidence of a myopathic process with normal 
nerve conduction testing. Echocardiogram did not reveal cardiomyopathy. Muscle 
biopsy of the right deltoid at 39 years revealed atrophy of myofibers without evidence of 
inflammation or rimmed vacuoles. Histochemistry revealed unremarkable stains for 
trichrome, NADH, SDH, ATPase (pH 9.4, 4.5), cytochrome oxidase, PAS, Oil red O and 
acid and alkaline phosphatase. Immunohistochemistry interestingly revealed that 
dystrophin C was completely absent and dystrophin N multifocally absent, however all 
other stains including spectrin, sarcoglycans, merosin, caveolin, dysferlin, emerin, 
Collagen IV, VI, and Laminin β1. EM did not reveal any subsarcolemmal deposits, no 
vacuolation and myofibrillar apparatus and vasculature appeared unremarkable. Tissue 
was poorly preserved for additional detailed analysis.  
 
Plain radiograph of the spine was done for loss of height. Cervical spine radiograph 
revealed compression deformity of C6 with approximately 80% loss of height. There 
was also evidence of a prior healed severe compression fracture of L2. Because of 
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concern for bone neoplasm a computed tomography (CT) was obtained. Cervical CT 
revealed a burst fracture of C6 vertebral body (Figure 2A), and osteolytic infiltrates 
involving the lateral masses, and spinous processes. Cortical retropulsion compromised 
the cervical spinal canal. Lumbar CT (Figure 2C) revealed a pathological fracture of the 
L2 vertebral body with approximately 80-90% loss of height. There was mild 
retropulsion compromising the lumbar spinal canal at the L2 vertebral body level. 
Trabecular thickening of the L4 vertebral body with mild loss in height was noted. There 
was also diffuse coarsening, mixed sclerotic and lytic changes in the right iliac bone 
considered to be Paget’s disease versus malignancy.  
 
MRI confirmed the CT finding showing severe C6-7 foraminal stenosis with mass effect 
observed on the spinal cord and both exiting nerves of the foramina and additionally 
revealed atrophy of the lower cervical muscles (Figure 2B), Severe atrophy of the 
lumbar paraspinal muscles (Figure 2D) and thigh muscle groups was noted (Figure 2E). 
A PET scan was completed to stage suspected lymphoma. Imaging revealed multiple 
areas of mild to moderate increased metabolic activity within bony structures including 
C6, T4, L2, and L3 vertebral bodies and multifocal areas of abnormality within the 
pelvis. These areas demonstrated areas of prominent bony trabecular thickening with 
patchy areas of both sclerosis and lucency.  
 
Bone biopsy for suspected malignancy of L2 showed irregular bony trabeculae with 
prominent osteoclastic and osteoblastic activity with areas of new bone formation. There 
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was no evidence of a neoplastic process and these results were considered most 
suggestive of Paget’s disease associated with an elevated alkaline phosphatase. 
 
Genetic testing for VCP was done because of the combination of PDB and myopathy. 
He was found to have a novel c.474 G>A VCP mutation, resulting in a change of the 
conserved methionine to isoleucine at amino acid position 158 (p.M158I) (Figure 7).  
 
His family history was significant for his grandfather (I:2) and father (II:1) dying of ALS at 
an unknown age, both of whom were suspected to carry the VCP gene mutation. There 
were no other relatives reported who manifested features of the familial disease. The 
ethnic background included mixed Dutch, Italian, Portuguese, and English. 
 
2.2. Family 2 (c.478 G>C; p.A160P) 
The proband is a 66 year old male (III:1) (Figure 1B) who was diagnosed with limb-
girdle muscular dystrophy in his mid-forties. He experienced loss of core muscle 
strength, difficulty lifting his arms above his head, using the stairs, getting out of a chair, 
and moving in bed. He has required a power chair since age 63 years. He reports 
shortness of breath when climbing stairs and has mild obstructive sleep apnea. He 
previously smoked 1 pack per day for 28 years. Physical examination was significant for 
camptomelia and scapular winging. Strength testing was significant for MRC right 4+/5 
shoulder abductor, 5-/5 elbow extensor, 4+/5 hip flexion, 5-/5 ankle dorsiflexion, and left 
4+/5 shoulder abductor, 5-/5 elbow extensor, 4+/5 hip flexors, and ankle dorsiflexion 5-
/5. Reflex testing of the triceps and patella were 1/4 bilaterally and his ankle jerk reflex 
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was absent bilaterally. Electromyography testing was completed at age 50 years testing 
the right tibialis anterior, vastus medialis, vastus lateralis, tensor fascia lata, iliopsoas, 
lumbar paraspinal muscles, deltoid, and left vastus lateralis and tibialis anterior. There 
was additional nerve conduction testing of the right and left peroneal and tibial nerves 
and sensory nerve testing of the right and left sural nerves. Testing revealed myopathic 
changes without neurogenic changes. His FBI exam nor routine clinical exam was not 
suggestive of FTD.  He also developed a pulmonary embolus at 50 years arising from a 
deep vein thrombus in his leg. He developed pain in his hips and lower back at age 52 
years. Bone scan revealed hot spots in multiple bones including T9, L3 spine, right 
scapula, bilateral femurs, and left humerus suggestive of PDB. He has been treated 
with alendronate sodium and more recently successfully with residronate. 
 
Muscle biopsy at age 57 years from his left quadriceps revealed mild myofiber size 
variability without evidence of inflammation or rimmed vacuoles. ATPase preparations 
at pH 4.3, 4.6, and 9.5 demonstrated a predominance of type II myofibers. NADH-TR 
staining revealed evidence of disruption of the intermyofibrillar network in the form of 
scattered target-like fibers suggestive of a primary neurogenic process. There was no 
evidence of increase in neutral lipid stores on Oil Red O stained preparations. Routine  
immunohistochemistry staining was unremarkable. Echocardiogram revealed mitral 
valve prolapse, left atrial enlargement,but no cardiomyopathy. Other medical problems 
included type 2 diabetes mellitus, macular degeneration, asthma, COPD, 
hypothyroidism, allergic rhinitis, colon polyps, and vitamin D and B12 deficiencies - 
common co-morbidities in the general population. 




On reviewing the family history (Figure 1B), his mother (II:2) had camptomelia related to 
Parkinson’s disease. His maternal grandfather (I:1) also had Parkinson’s in his late 
forties, both suspected to have VCP disease. There was no other pertinent family 
history. The ethnic background is Austro-Hungarian.  
 
In view of his clinical spectrum of myopathy and PDB, genetic testing for VCP at age 64 
years led to a diagnosis of VCP disease. He was identified with a novel c.478 G>C 
mutation which resulted in a protein change in the conserved alanine to proline at 
position 160 (p.A160P) in the VCP gene (Figure 7). 
 
2.3. Family 3 (c.383G>C; p.G128A) 
The proband (III:1) (Figure 1C) a 57 year old male reported difficulty raising his hands 
over his head since childhood. He recalls that at age 16 years he broke his clavicle in a 
motorcycle accident because he did not have enough strength in his arms and 
shoulders to turn his bike and avoid being hit by a car.  He developed noticeable 
proximal lower extremity weakness and difficulty climbing stairs beginning at age 40 
years. Muscle cramps, muscle twitching, numbness in feet and constant back pain were 
also reported. On physical examination he had difficulty walking on his toes and was 
noted to have atrophy of shoulder girdle muscles and bilateral scapular winging. 
Routine clinical exam  revealed an MRC scale of 4+ of the deltoids, triceps and 
iliopsoas, 5- of the biceps, and 5/5 of the other muscle groups. Tendon reflexes  was 
2+/4. He was alert and oriented in time and place and routine testing including FBI 
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testing was not suggestive of FTD. Laboratory abnormalities include an elevated CPK, 
liver enzymes (ALT, AST) and an elevated ALP (Table 1).  
 
EMG showed neurogenic and myopathic changes in several muscles of his right upper 
and lower extremities. Muscle biopsy at age 52 years also showed features of 
dennervation-reinnervation and inclusion body myopathy. Histology revealed marked 
variation in fiber size and shape with many angular fibers in groups and scattered, 
several fibers with rimmed vacuoles, few fibers with multiple intracytoplasmic 
eosinophilic inclusions, and no abnormalities on routine staining (Figure 3), except for a 
few fibers that were devoid of cytochrome oxidase staining. In particular there were no 
rubbed out fibers or significantly increased amount of COX negative or SDH positive 
fibers. Lumbosacral spine radiographs at 53 years revealed sclerosis involving the 
posterior elements of L2 and L5 (Figure 4A). X-ray of the tibia and fibula show a mild 
abnormality in the left fibula consistent with PDB. Skull X-ray showed patchy lytic areas 
in the calvarium bilaterally mostly involving the vertex but some noted to be present 
anteriorly. Pelvic X-ray view reveals course trabecular pattern and abnormal cortical 
thickening of the right ilium and right proximal femur. MRI of the cervical, thoracic and 
lumbar spine revealed degenerative changes and, importantly, fatty infiltration of the 
paraspinal muscle (Figure 4B). Bone scan at age 49 years revealed elevated tracer 
activity in skull, left scapular, L2, L5, the right anterior ilium, the proximal right femur, the 
left fibula, and left foot  consistent with his diagnosis of PDB (Figure 4C). 
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Other clinical conditions included fatty infiltration of the liver hypothyroidism, B12 
deficiency and a torn anterior cruciate ligament. Thyroid scan revealed left thyroid 
nodule.  
 
On review of his family history, his mother (II:4) had PDB and muscle weakness, loss of 
muscle mass,  trouble speaking and swallowing suggestive of ALS and passed at age 
67 years. His maternal grandmother (I:4) had muscle weakness beginning at age 20 
years was diagnosed with PD at age 30 years and died at age 54 years. He has three 
brothers, one of whom age 48 years has been diagnosed with ALS, all these relatives 
were suspected of having VCP disease. The ethnic background is mixed Caucasian. 
 
VCP myopathy was suspected because of his clinical features of muscle weakness, 
muscle biopsy findings of rimmed vacuoles, and PDB. Genetic testing revealed a 
c.383G>C mutation which resulted in a change of a conserved glycine at position 128 to 
alanine (p.G128A). 
 
2.4. Family 4 (c.382G>T; p.G128C) 
The proband (II:1) (Figure 1D) is a 55 year old male of Finnish ancestry whose first 
symptoms were ankle weakness occurring at age 35 years. Within 2-3 years, proximal 
lower limb weakness was evident, with falls, and difficulty climbing stairs. He 
subsequently developed proximal upper limb weakness from age 40 years progressing 
to wheelchair use at the age of 50 years. On examinations at the age of 55 years he 
had extensive muscular atrophy of the proximal muscles with marked scapular winging 
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and distal weakness resulting in testing for FSHD which was negative. Proximal muscle 
strength was at an MRC scale of 1-2/5 in all muscle groups except for elbow extension 
(4/5) and hip adduction (3-4/5). No facial weakness was noted and routine clinical exam 
including FBI exam was not suggestive of FTD. CK was mildly elevated at 350 IU/L, 
EMG was clearly myopathic. A biopsy of the anterior tibial muscle at the age of 38 years 
showed dystrophic changes with rimmed vacuoles and a few cytoplasmic bodies. 
Vacuolated fibers showed sarcoplasmic aggregates without myonuclear aggregates 
with SMI-31, TDP-43 and p62 antibodies (Figure 5).  
 
Muscle MRI (Figure 6) showed extensive dystrophic fatty replacement with minimal 
sparing of the rectus femoris. The patient did not have features of FTD or PDB.  
 
Review of family history was negative and parents lived to an advanced age without 
evident bone or brain disease, however were not available for DNA segregation studies. 
 
Genetic testing via Sanger sequencing revealed a novel c.382G>T VCP mutation 
causing a change of a conserved glycine at position 128 to cysteine (p.G128C) thus 
confirming the diagnosis of VCP myopathy. 
 
Table 1 summarizes the clinical features of the affected individuals in the four families 
with novel mutations. Of note, most individuals were diagnosed because of the 
coexistence of the two most common features: myopathy +/- rimmed vacuoles and/or 
PDB, though family 4 did not have associated PDB but was diagnosed because of the 
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muscle biopsy findings. Three of the four families had a family history of ALS and/or 
Parkinson’s disease.  
 
In addition, we performed an in silico analysis to evaluate the impact of these mutations 
on protein function as the result of a single codon change. We used several prediction 
tools due to reported differences in tool performance with variable outcomes [39, 40]. 
Table 2 summarizes the variable mutation prediction for the four novel mutations 
identified in the families [41-45]. Dispite the inconsistencies of in “silico” prediction, all of 
these mutations were associated with a distinct disease phenotype segregating in the 
families, and therefore considered causative disease mutations rather than simple 
polymorphisms. 
 
3. Discussion  
Herein we report patients with four novel mutations to expand the genotypic spectrum of 
VCP disease most commonly characterized by progressive limb-girdle IBM, PDB, FTD, 
but also ALS and Parkinson’s disease.  
 
Two of the novel mutations c.383G>C, and c.382G>T, affecting p.G128 located on exon 
4, appears to be a hot spot locus. The remaining two mutations, c.474 G>A, p.M158I 
and c.478G>C, A160P are located in exon 5 which is involved in ubiquitin and cofactor 
binding. The p.Ala160 residue is conserved among VCP proteins from human to fish, 
and substitutions of nearby amino acids (e.g., p.Arg155His, p.Gly157Arg, p.Arg159His) 
are reported to be pathogenic and causative for this disorder [1, 46, 47].  




Both of these exons are part of the N-terminal domain (NTD) (Figure 7). Proper function 
of the VCP protein has been thought to rest in the balanced binding to its various 
cofactors [48] which the NTD is likely involved in [49, 50]. A recent study found that 
mutations of the NTD attenuate small ubiquitin-like modifier-ylation (SUMOylation) of 
VCP which weaken hexamerization during stress [51]. Several residues within the NTD, 
specifically R155, R159, and R191 are implicated in significant interactions with 
downstream residues in the D1 domain [52]. Indeed, the D1 domain’s primary 
responsibility appears to be hexamerization [53] though the mobility of this domain is 
also essential for ATP hydrolysis [20]. Although mutated VCP has not been shown to 
alter gross hexamer formation [54], a possible effect of mutation to the NTD is to 
attenuate stability of the protein during stress with or without altering affinity to its 
cofactors. Most symptomatic VCP mutations occur near the NTD highlighting the 
essential function of this domain (Figure 7). 
 
Muscle weakness among individuals studied in this report varied from a definite pattern 
of limb-girdle weakness with mixed distal and proximal limb involvement. EMG results 
were myopathic in three families with one family showing a mixed myopathic and 
neurogenic pattern although our patients did not exhibit features of ALS. Previous 
studies describe 31.2% of patients having pure myopathic changes while 13.7% having 
mixed myopathic-neuropathic changes on their EMGs [2]. Pure neurogenic changes 
may occur with a frequency of 30% [55]. All four individuals in the report had mildly 
elevated CPK levels as was previously reported by Mehta et al (2013) (CPK level 165.2 
±149.6 IU/l range IU/L, normal range 22-198 IU/L) [2]. 




Muscle biopsy results typically included nuclear clumps, angulated fibers, and rimmed 
vacuoles without amyloid fibrils [56]. The most characteristic finding of rimmed vacuoles 
was only present in two of the four patients in this report highlighting the phenotypic 
variability of this disease.   
 
Among our patients three of the families had PDB as a major feature presenting at an 
average age 47 years. The most striking feature was the advanced manifestations of 
PDB in one patient resulting in collapse of the C6 and L2 vertebral bodies and an 
extensive workup for a neoplasm because of the lack of awareness of the association of 
PDB with myopathy. Early treatment could have prevented the severe complications of 
PDB. Compression fractures in PDB tend to occur with higher frequencies in the lumbar 
spine [57] with L4/5 the most commonly affected lumbar vertebrae [58]. Cervical spine 
involvement is less commonly found. The only presenting symptoms associated with 
PDB in Families 2 and 3 was bone pain. All three with PDB had elevated alkaline 
phosphatase (ALP) (average 192.5 IU/L (normal 44-147 IU/L) a simple test permitting 
early diagnosis and optimal treatment of PDB in VCP disease [4]. Twenty-two percent of 
patients with PDB are asymptomatic when diagnosed [59], highlighting the benefit of 
regular screening for PDB with blood ALP and bone scans. Early diagnosis and 
treatment with long acting bisphosphonates may prevent the severe complications of 
undetected or untreated PDB such as reduced height, pathologic fractures, and bone 
deformities [2]. Farpour et al. (2012) studied radiological features of PDB in 17 patients 
with clinical manifestations of the VCP mutation and found evidence of PDB in 10 
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individuals; skeletal survey included thickening of the calvarium, sclerosis and 
enlargement of the lumbar vertebrae, pelvis, femurs, and humeri and only one individual 
had a slightly thickened cervical C5 vertebral body [60]. The severe compression 
deformity of C6 with approximately 80% loss of height and severe compression fracture 
of L2 seen in Case 1 and involvement of the fibula and foot in Case 3 are unique in 
association with VCP disease [60].   
 
Unlike previous reports, none of our patients developed FTD which may be related to 
their particular genotypes. FTD is reported to affect a third of VCP disease patients and 
is typically seen at a mean age of 57 years, thus some of the patients may not be old 
enough to manifest it [4]. 
 
There are now several case reports of patients with VCP disease with Parkinson’s 
disease [5, 17, 61, 62]. Lewy Bodies are the pathological hallmark of Parkinson’s 
disease and VCP protein is a known component of the Lewy bodies [63].  Forman et. al 
(2006) [13] described a patient with IBMPFD having Lewy bodies on neuropathological 
examination though the patient exhibited no signs or symptoms of Parkinson’s disease 
or dementia. The prior case reports and the pathological finding suggests that 
Parkinson’s disease should now be considered as a feature of VCP disease. VCP 
disease and Parkinson’s disease share significant involvement of mitochondrial 
autophagy, or mitophagy, in their common pathogenesis. Mitophagy is an essential part 
of cellular quality control, failure of which has been shown to elevate levels of reactive 
oxygen species, therefore elevating cellular stress levels [64]. VCP interacts with PINK1 
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and parkin, key mitophagy proteins important in the clearance of damaged mitochondria 
[65-69]. Mutations in these two genes are involved in the etiology of Parkinson’s 
disease in vivo  [69].   
 
Urinary and fecal incontinence was reported in the proband in family 1. Fecal 
incontinence has been reported in association with VCP myopathy in other families 
secondary to autonomic dysfunction, therefore these features are considered part of the 
spectrum of the phenotype associated with VCP disease [38, 70]. 
 
Although the disease is rare, the enormous intra- and interfamilial variation commonly 
results in misdiagnosis of many patients with VCP disease as exemplified in the case 
reports of our cohort. The enormous variation was also highlighted in a recent study 
portraying a Brazilian family with three first degree members each expressing a unique 
symptom including myopathy, ALS, and FTD [32]. VCP disease should always be 
considered in families with members of the families affected by one or more 
components of the disease: Limb-girdle muscular dystrophy, FSHD, IBM, PDB, FTD, 
ALS, Parkinson’s disease and Alzheimer’s disease. Our study furthers the genotypic 
spectrum of the disease, allowing clinicians to diagnose the disease in patients with the 
same mutations but varying manifestations. Future studies of VCP disease will identify 
the underlying mechanism for the wide phenotypic variation and its relationship with 
related neurological disorders.  
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Targeted therapies are being developed for several neuromuscular/neurodegenerative 
disorders. Better understanding of the mechanism will also permit targeted drug therapy 
for VCP disease. Recently Zhang et al. (2017) reported their studies in a drosophila 
model and indicated that VCP negatively regulates mitofusin, and disease mutations act 
as hyperactive alleles. They showed that VCP inhibitors NMS-873 and ML240 corrected 
the mitofusin downregulation, mitochondrial fusion defect, muscle damage and cell 
death in Drosophila and patient fibroblasts [68], and are a promising new treatment for 
patients. It is therefore important to diagnose patients early in order to prevent 
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Figure 1. Pedigree of families 1-4. Arrow indicates proband. The filled upper right quadrant indicates 
myopathy, filled right lower quadrant indicates Paget’s disease of bone, filled upper left indicates 
amyotrophic lateral sclerosis, and filled lower left indicates Parkinson’s disease. 
 
Figure 2. Imaging studies of the proband (Individual III:1) of family 1. (A) Computed tomography (CT) 
of cervical spine revealed a compression deformity and fracture of C6 with approximately 80% loss of 
height. (B) Cervical magnetic resonance imaging (MRI) revealed atrophy of the lower cervical 
paraspinal muscles.  (C) Lumbar CT revealed a pathological fracture of the L2 vertebral body with 
approximately 80-90% loss of height. (D) Severe atrophy of the lumbar paraspinal muscles and (E) 
moderate atrophy of thigh muscle groups was noted. 
Figure 3. Muscle biopsy of proband (individual III:1) family 2 from left quadriceps at age of 62 years.  
Hematoxylin and eosin (H&E) stains showed marked variation in fiber size and shape with many 
angular fibers, some rimmed vacuoles (arrows), few fibers with multiple intracytoplasmic eosinophilic 
inclusions, and minimal inflammation. 
 
Figure 4. Radiology of proband (individual III:1) from family 3. (A) Lumbosacral frontal radiograph 
reveals Paget disease of L2 and L5. (B) MRI of the lumbar spine revealed fatty infiltration of the 
posterior paraspinal muscles. (C) Bone scan at age 49 years reveals hot spots suggestive of Paget 
disease of bone in skull, left scapular, L2, L5, the right ilium, the proximal right proximal femur, the left 
fibula, and left foot. 
 
Figure 5. Muscle biopsy from tibialis anterior muscle from patient 4 at the age of 38 years. Dystrophic 
features include atrophic fibers, excess of fat and fibrosis as well as numerous rimmed vacuoles were 
observed. Vacuolated fibers showed aggregates with SMI-31 (A), TDP-43 (B) and p62 (C) antibodies. 
 
Figure 6. Radiology of patient (individual II:1) from family 4. MRI T1 imaging of the patient shows 
significant fatty replacement of all thigh muscles. 
 
Figure 7. Known and novel mutations in VCP in individuals. (A) Functional domains and mutations of 
VCP. Arrows indicate the locations of mutations relative to the exon-intron structure, where the exons 
are numbered 1–17. The relative positions of the N-terminal domain (CDC48, navy), flexible linker 
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(L1, yellow), first AAA-ATPase domain (D1, green), linker region (L2, light blue), second AAA ATPase 
domain (D2, red) and C-terminal domain (black) are indicated, and the 5′ and 3′ untranslated regions 
are shown in white. Novel mutations are highlighted in red and mutations associated with Parkinson’s 
is indicated by an asterisk (B) Species conservation of amino acid residues mutated in IBMPFD, with 
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Table 1, Clinical and laboratory data for affected individuals. 
Case Age 
(years) 




















45 M + + 39 39 243 216 Neurogenic  & 
myogenic 
features 

























55.5 4 M 75% 100% 47.0 39.8 192.5 405.3 100% 
myogenic; 25% 
neurogenic 
50% 50% - 
 PDB Paget’s disease of bone, ALP alkaline phosphatase (44 to 147 IU/L), CPK total creatinine phosphokinase (NL 22 to 
198 U/L), EMG electromyography, NCS nerve conduction study, FH family history, ALS amyotrophic lateral sclerosis. 
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Table 2. Prediction of Likely Impact of Novel Variants.  
 Family 1 Family 2 Family 3 Family 4 
Point Mutation c.474G>A c.478G>C c.383G>C c.382G>T 
Chr:Pos 9:35065350 9:35065346 9:35066734 9:35066734 
AA subs M158I A160P G128A G128C 
UMD score  72 84 75 93 
UMD Prediction  Prob. Pathogenic  Pathogenic Pathogenic Pathogenic 
PolyPhen2 Score  0.887 0.001 1 1 
PolyPhen2 Prediction Possibly damaging  Benign Probably damaging  Probably damaging  
SIFT Score  0.37 0.44 0.02 0.01 
SIFT Prediction  Tolerated  Tolerated  Damaging  Damaging  
Provean Score -2.98 -0.949 -5.015 -7.644 
Provean Prediction  Deleterious Neutral Deleterious Deleterious 
Mutation Taster  Score  10 27 60 159 
Mutation Taster Prediction  Disease Causing Disease Causing Disease Causing Disease Causing 
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